阿比特龙联合多西他赛对前列腺癌患者的有效性及安全性评价

金姗静 陈海飞 王建新

[摘要] 目的 探讨阿比特龙联合多西他赛临床治疗前列腺癌（PCa）患者的有效性及安全性。 方法 选择2018年4月至2019年3月在我院接受治疗的70例前列腺癌患者，依据随机数字表法分为联合组、对照组，各35例，两组均给予常规口服泼尼松片，对照组在此基础上静脉滴注多西他赛，联合组在对照组基础上加用阿比特龙片进行治疗。比较两组患者治疗前后的特异性前列腺抗原（PSA）、血清白蛋白（ALB）、血清前蛋白（PA）及中性粒细胞计数、谷丙转氨酶及睾酮水平，观察两组患者临床疗效及不良反应发生情况。 结果 两组治疗前PSA、ALB、PA、中性粒细胞、谷丙转氨酶、睾酮指标比较，差异无统计学意义（P>0.05）;与治疗前比较，两组治疗后ALB、PA、谷丙转氨酶指标升高，PSA、中性粒细胞计数、睪酮指标降低，差异有统计学意义（P<0.05）;与对照组比较，联合组ALB、PA、中性粒细胞计数水平较高，PSA、谷丙转氨酶、睾酮水平较低，差异有统计学意义（P<0.05）;对照组临床有效率低于联合组，但差异无统计学意义（P>0.05）;联合组不良反应总发生率高于对照组，差异无统计学意义（P>0.05）。 结论 阿比特龙联合多西他赛治疗前列腺癌患者临床效果优秀，优化患者各项指标表达，且安全性更高，值得临床应用推广。

[关键词] 阿比特龙;多西他赛;前列腺癌;特异性前列腺抗原

[中图分类号] R737.25          [文献标识码] B          [文章编号] 1673-9701（2021）36-0097-04

Efficacy and safety of abiraterone combined with docetaxel in patients with prostate cancer

JIN Shanjing1   CHEN Haifei1   WANG Jianxin2

1.Operating Room， Taizhou First People's Hospital in Zhejiang Province， Taizhou   318020， China; 2.Uropoiesis Surgical Department， Taizhou First People's Hospital in Zhejiang Province， Taizhou   318020， China

[Abstract] Objective To investigate the efficacy and safety of abiraterone combined with docetaxel in the clinical treatment of patients with prostate cancer （PCa）. Methods A total of 70 patients with prostate cancer treated in our hospital from April 2018 to March 2019 were selected. They were divided into the combination group and the control group using random number table method， with 35 patients in each group. Both groups were given conventional oral prednisone tablets. The control group were given additional intravenous docetaxel， and the combination group were given additional abiraterone tablets combined with intravenous docetaxel. The specific prostate antigen （PSA）， serum albumin （ALB）， serum proprotein （PA）， neutrophil count， alanine aminotransferase and testosterone before and after treatment were compared between the two groups. The clinical efficacy and incidence of adverse events were observed in both groups. Results There were no significant differences in PSA， ALB， PA， neutrophils， alanine aminotransferase， and testosterone indicators between the two groups before treatment，the difference was not statistically significant （P>0.05）. After treatment， the ALB， PA， and alanine aminotransferase indicators were increased in both groups， and PSA， neutrophil count， and testosterone indicators were decreased in both groups， the difference was statistically significant （P<0.05）. The levels of ALB， PA， and neutrophil count in the combination groups were higher than those in the control group， and the levels of PSA， alanine aminotransferase， and testosterone in the combination group were lower than those in the control group， the difference was statistically significant （P<0.05）. The clinical effective rate in the control group was lower than that in the combination group， but the difference was not statistically significant （P>0.05）. The total incidence of adverse events in the combination group was higher than that in the control group， the difference was not statistically significant （P>0.05）. Conclusion Abiraterone combined with docetaxel has excellent clinical effects in the treatment of patients with prostate cancer. It can optimize expression of various indicators with higher safety. It is worthy of clinical application and promotion.

[Key words] Abiraterone; Docetaxel; Prostate cancer; Prostate specific antigen

前列腺癌（Prostatecancer，PCa）属于泌尿科男性比较常见的恶性肿瘤疾病，患病初期没有明显症状，后期治愈难度大，且死亡率高[1]。目前前列腺癌患者接受的治疗方式主要是用药、手术抑制，但绝大部分患者在治疗后，会由激素敏感性前列腺癌发展为去势抵抗性前列腺癌，治疗难度变高[2]。……